Mutational profile and haematological response to iron chelation in myelodysplastic syndromes ( MDS )-Reference-Cited by-同舟云学术

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes ( MDS )

Published:2018-11-08 Issue:5 Volume:185 Page:954-957
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Fabiani Emiliano¹^ORCID,Calabrese Chiara²,Niscola Pasquale³,Balleari Enrico⁴,Molteni Alfredo⁵,Finelli Carlo⁶,Falconi Giulia¹,Fenu Susanna⁷,Fianchi Luana⁸,Criscuolo Marianna⁸,Salvi Flavia⁹,Lavorgna Serena¹,Buccisano Francesco¹,Maurillo Luca¹,Lo Coco Francesco¹,Cilloni Daniela²,Voso Maria Teresa¹^ORCID

Affiliation:

1. Department of Biomedicine and Prevention Universita’ Tor Vergata RomeItaly

2. Department of Clinical and Biological Sciences University of Turin OrbassanoItaly

3. Department of Haematology S. Eugenio Hospital RomeItaly

4. Department of Haematology and Oncology IRCCS AOU San Martino ‐ IST GenovaItaly

5. Haematology ASST Grande Ospedale Metropolitano Niguarda MilanItaly

6. Department of Haematology S. Orsola‐Malpighi Hospital BolognaItaly

7. Haematology Department Az. Osp. San Giovanni‐Addolorata RomeItaly

8. Dipartimento Scienze Radiologiche Radioterapiche ed Ematologiche Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

9. Department of Haematology AO SS Antonio e Biagio e C. Arrigo Alessandria Italy

Funder

Associazione Italiana Ricerca sul Cancro

Beat Leukaemia Foundation Milano

Società Italiana Ematologia Sperimentale

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15655

Reference10 articles.

1. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

3. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

4. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

5. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phospholipase C beta1 (PI‐PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron‐induced oxidative stress in myelodysplastic syndromes (MDS);The FASEB Journal;2020-09-22

2. Less iron improves MDS haematopoiesis;British Journal of Haematology;2019-06-06

3. Could haemochromatosis ( HFE ) gene mutations affect response to iron chelation in myelodysplastic syndrome?;British Journal of Haematology;2019-05

4. Could haemochromatosis ( HFE ) gene mutations affect response to iron chelation in myelodysplastic syndrome? – Response to Lucijanic and Kusec;British Journal of Haematology;2019-05